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Highlights 
 In univariate analysis older and male patients had worse COVID-19 outcomes
 Nearly two-thirds of patients hospitalized with COVID-19 were African American
 Hypertension was the most frequent co-morbidity in hospitalized  COVID-19 patients
 qSOFA scores, bilateral infiltrates, white counts and blood urea nitrogen levels  help
prognosticate
 In univariate analysis d-dimer > 575.5 ng/mL had an odds ratio of 10.5 for mechanical
ventilation
 Caring for COVID-19 is resource intensive with long lengths of stay (mean 10.7 days)
Abstract: 
Background: COVID-19 is a novel disease caused by SARS-CoV-2. 
Methods: We conducted a retrospective evaluation of  patients admitted with COVID-19 to one 
site in March 2020. Patients were stratified into three groups: survivors who did not receive 
mechanical ventilation (MV), survivors who received MV and those who received MV and died 
during hospitalization. 
Results: There were 140 hospitalizations; 22 deaths (mortality rate 15.7%), 83 (59%) survived 
and did not receive MV, 35 (25%) received MV and survived; 18 (12.9%) received MV and died. 
Thee mean age of each group was 57.8 , 55.8 and 72.7 years respectively (p=.0001). Of those 
who received MV and died,  61% were male (p=.01). More than half the patients ( n=90, 64%) 
were African American. First measured d-dimer >575.5 ng/mL, procalcitonin > 0.24 ng/mL, LDH 
> 445.6 units/L and BNP > 104.75 pg/mL had odds ratios of 10.5, 5 , 4.5  and 2.9 respectively for
MV  (p < .05 for all). Peak BNP > 167.5 pg/mL had an odds ratio of 6.7 for inpatient mortality
when mechanically ventilated (p= .02).
Conclusions: Age and gender may impact outcomes in COVID-19. D-dimer, procalcitonin, LDH 
and BNP may serve as early indicators of disease trajectory.  
Background 
A cluster of cases of pneumonia of unknown etiology in Wuhan, China were reported to the 
World Health Organization on December 31, 2019. Subsequently, the causative agent was 
identified as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the 
associated disease was named COVID-19. By June 19, 2020, 117,472 deaths in the United States 
were attributed to COVID-19.(1) 
Clinical characteristics of the disease and predictors of mortality have been described in 
patients from China, Italy and from cohorts in the Seattle and New York City region.(2,3) (4,5) In 
order to further our understanding of the disease, it is important to describe its course in 
multiple settings to determine the consistency of previously described features and to validate 
any emerging patterns.  
We describe all consecutively admitted patients with COVID-19 to our institution between 
March 1 and March 31, 2020 to both characterize the population that requires hospitalization 
and to explore prognostic indicators.  
Methods 
The protocol was reviewed by the local Institutional Review Board and deemed exempt. 
The study was conducted at a large, academic, Midwestern institution which serves as a referral 
center for the State of Indiana. Surge planning allowed our institution to accommodate up to 
278 patients with COVID-19 who may require intensive care and up to 400 patients who may 
require medical-surgical or progressive levels of care. The first patient with testing confirmed 
COVID-19 was admitted to our hospital on March 11, 2020. 
Initially, polymerase chain reaction (PCR) based testing was available through coordination with 
the State Department of Health for all patients. PCR testing became available within the 
institution on March 18, 2020. A list of all patients who present to the hospital and have testing 
performed is maintained by our infection preventionist (KK). We used this list to identify all 
patients admitted to the hospital between March 1 and March 31, 2020 whose test results 
indicated infection by the novel coronavirus.  
A data collection form was created in REDCap, a secure web-based tool to facilitate research 
(data collection form available as supplementary material).(6) Items included demographics, co-
morbid conditions, clinical presentations, time stamped laboratory values and hospital course. 
Data collection was discussed and operationalized between three authors who reviewed the 
electronic medical record of each patient (WG, EC, AK). The form was pilot tested and edited to 
enhance ease of use and consistency. Each patient’s admission history and physical was 
reviewed and corroborating diagnostic information was retrieved when relevant (e.g. 
hemoglobin A1c for patients with diabetes mellitus). Presenting symptoms were categorized as 
1- respiratory complaints (cough, shortness of breath, chest pain), 2- gastrointestinal (GI) 
complaints (nausea, vomiting, diarrhea, abdominal pain), 3- fever, 4-syncope and altered 
mental status, 5- constitutional symptoms (myalgias, anosmia, dysgeusia, anorexia, night 
sweats, fatigue and weakness). The first recorded set of vital signs, imaging and laboratory data 
was captured. Vital signs and respiratory care notes were reviewed to assess the timing and 
magnitude of increasing oxygen needs. Laboratory data was reviewed for the entire hospital 
stay. The timing and values of first drawn possible prognosticators were recorded and peak 
values and timing were captured when these laboratories were checked more than once. 
Medications prior to admission were determined by reviewing the pharmacist’s admission 
medication history. The medication administration record was accessed to confirm the receipt 
of COVID-19 specific therapies, steroids and vasopressors. The discharge summary was 
reviewed for complications. All patients admitted for confirmed or suspected COVID-19 during 
the study period at our institution had a complete blood count (CBC) and basic chemistries 
drawn on admission. Timing of prognostic laboratories and clinical trajectories were reported 
relative to the timing of this admission CBC. Data were collected for all patients until June 5, 
2020. 
 
Data were then downloaded from REDCap and described using descriptive statistics. We 
stratified the sample into three distinct groups of worsening severity based on outcomes: 
patients who did not receive mechanical ventilation (MV) and survived, those who received MV 
and survived, and those who received MV and died during the hospitalization.  
 
Laboratory values that may serve as markers of disease severity were compared among these 
three  groups. Based on prior research, laboratory values that were tracked included alanine 
transaminase (ALT), brain natriuretic peptide (BNP), creatine kinase (CK), c-reactive protein 
(CRP), d-dimer, ferritin, lactate dehydrogenase (LDH), procalcitonin and troponin. First and peak 
recorded values were retrieved and compared using analysis of variance testing. If testing 
revealed statistically significant differences in values between groups at p < 0.05 , odds ratios 
were then calculated. At the time of presentation, concerns about the trajectory of patients 
with COVID-19  often revolve around whether the patient will require MV; and shift towards 
survival once MV is necessary. To parallel these clinical questions, the first measured values 
were used to calculate the odds of receiving MV, while peak values were used to calculate the 
odds of inpatient mortality in those who received MV. The 75th percentile value in the group 
that did not receive MV and survived was used as the cut-off to calculate the odds for receiving 
MV, while the 75th percentile value in those who received MV and survived was used as the cut-
off to calculate the odds of mortality in those who received MV. The timing of both the first and 
peak prognostic laboratory values relative to the admission CBC time were also compared 
between the three groups.  
 
Data was analyzed using the pandas package for Python, with Fisher’s exact testing used for 
categorical variables and contingency tables. Analysis of variance (ANOVA) testing was 
performed for continuous variables, using the SciPy STATS package.(7)Characteristics of the 
sample were compared between the three outcome groups. 
Results 
Between March 1-March 31, 2020, there were 140 admissions to the hospital with testing 
confirmed COVID-19. More than half (59.3%) of the sample did not receive MV.  
There were a total of 22 deaths (15.7% mortality rate) however, 4 patients had goals of care 
that were focused on comfort and did not receive MV. Of those who received MV, 35 (66%) 
survived. 
Demographics and Co-morbidities 
Overall the sample had roughly equal numbers of males and females; however, 68% of those 
who received MV were male. The mean age of those who received MV and died  was 73 years 
while the mean age of those who received MV and survived was 55.8 years. More than half the 
sample (64%) was African American and 67% of those who did not survive MV were African 
American. Gender and age distribution were statistically significantly different between the 
three outcome groups. (Table 1) 
Hypertension and diabetes mellitus were the most frequently noted co-morbidities with the 
overall sample having a mean of 2.9 co-morbidities per patient. The mean number of 
outpatient medications at the time of admission per patient was 7.6. Patients had few inpatient 
stays in our hospital system before the current encounter with a mean of 0.4 hospitalizations 
per patient over the prior 12 months. 
The group that received MV and survived had the highest mean body mass index (BMI) (36) and 
the lowest proportion of individuals with normal BMIs. The mean BMI for those who received 
MV and did not survive was 27.2 which was lower than the mean BMI for the group who did 
not receive MV (32.3). (p <.05 for all pair-wise comparisons of BMI) 
Presenting Symptoms and Initial Evaluation 
Most patients presented with multiple symptoms, however patients who received MV and died 
reported fewer symptoms on presentation. Symptoms related to the respiratory system were 
the most frequent (93.6%) followed by reports of fever (65%) and GI complaints (51%). Fewer 
patients who received MV and died reported fever on admission and reported shorter duration 
of symptoms at the time of presentation. (Table 2)   
While fever was a common complaint, the first mean recorded temperature for all groups was < 
38C. More than half the sample (52%) met systemic inflammatory response (SIRS) criteria on 
admission: however, the distribution of the mean quick sequential organ failure assessment (Q 
SOFA) score differed between the three groups with the highest mean score noted in those 
who received MV and died. (8) 
Initial chest X-ray imaging was normal in 13.6 % of presentations and  bilateral infiltrates were 
the most commonly noted abnormality (69%). Bilateral infiltrates were less frequently observed 
in those who did not receive MV and survived. 
 
Mean presenting white counts, absolute neutrophil counts and blood urea nitrogen (BUN) 
values were noted to be highest amongst those who received MV and died.  
 
Only 3% of patients had a co-infection detected by respiratory viral panel testing. 
 
Clinical Trajectory  
 
Upon initial presentation, 79 patients (56%) did not receive supplemental oxygen while 26 
(18.6%) did not receive any supplemental oxygen throughout the stay. 
 
In patients who did not receive MV support and survived, the mean peak oxygen requirement 
by nasal cannula was 5.1 liters. If needs were not met by nasal cannula, the  mean peak FiO2 
was 42.5%. These peak needs were reached in a mean of 32.4 hours following admission. 
 
Patients who received MV and survived had a mean peak pre-intubation requirement of 12.1 
liters by nasal cannula or mean FiO2 80% when nasal cannula did not suffice, reaching this peak 
in a mean of 35.9 hours following admission. In those who received MV and died, mean peak 
pre-intubation requirements by nasal cannula were 10.25 liters or  FiO2 72.5%. These peak 
needs were reached in a mean of 36.1 hours following admission. (Supplementary Table 1) 
 
The mean time to MV  from admission in those who survived was 30 hours and for those who 
died was 52.5 hours. (p=.1) 
 
Laboratory values and Prognostication 
 
Laboratory values that showed differences in distribution between groups with p-value <0.05 in 
the first reported values included BNP, d-dimer, LDH and procalcitonin. Odds ratio using the 
specified cut-offs for receiving MV were statistically significant for each of these laboratory 
values with the highest odds ratio (10.5) for receiving MV noted for d-dimer values elevated 
above 575.5 ng/mL. (Tables 3 and 4) 
 
ALT, BNP, CK, CRP, d- dimer IL-6 and LDH values were statistically different between the groups 
at peak and were used to calculate the odds for mortality in patients receiving MV. At the 
thresholds used, only peak BNP achieved statistical significance with levels elevated above 
167.5 pg/mL associated with a 6.8-fold increased risk for mortality in patients receiving MV. 
(Tables 3 and 4) 
 
Ferritin and troponin did not achieve statistically significant differences between groups at 
either first or peak measured values.  
 
The timing of first reported laboratory values relative to admission CBC were similar between 
the three groups , however there were statistically significant differences in when peak values 
of CK ,CRP, ferritin, procalcitonin and troponin were achieved between the groups. (Table 3) 
 
 
Treatment 
 
Most (n=109, 78%) patients received at least one dose of hydroxychloroquine during the course 
of the hospitalization. At least one dose of azithromycin was given in 68% (n=95) of cases. Six 
(4%) patients received tociluzimab and one (0.7%) received remdesivir. Systemic steroids were 
administered in 44 (31%) patients.  
 
Outcomes and Complications 
 
The mean length of stay was 6.5 days for patients who did not receive MV and 21.3 days for 
those who received MV and survived (p <.00001). 
 
Shock requiring vasopressors was noted in 54.3% of those who survived MV and in 77.8% of 
those who received MV and died. Secondary bacterial infection which included pneumonia and 
bacteremia was common amongst those who received MV (noted in 42.9% of survivors who 
received MV and in 44.4% of those who received MV and died).  Venous thromboembolism 
occurred in 3.6% of patients who did not receive MV and survived, in 20% of those who 
received MV and survived and in 27.8% of those who received MV and died. The 14-day 
readmission rate was 8.4% for those who did not receive MV and 11.4% for those who did. 
Renal failure necessitating the initiation of renal replacement therapy was noted in a third of 
those who received MV and died. (Table 5) 
 
 
Discussion 
 
We present in rich detail the clinical characteristics, laboratory evaluation, trajectories and 
outcomes of all patients admitted with COVID-19 to our institution in March 2020 and explore 
prognostic implications of certain clinical and laboratory markers. 
 
Our data corroborates the increased risk of severe disease and mortality in COVID -19 conferred 
by increasing age and male gender noted in previous studies. An early US report found a 
mortality rate of 67% in patients admitted to the intensive care unit where the mean age of the 
population was 70 years, and more serious illnesses in the US have been noted in older 
adults.(9,10) In our sample, while more males received ventilatory support than females, these 
differences were less marked than the initial data from China where 85% of those who required 
ICU care were male.(4) Data from hospitalized patients in the New York City area also noted 
worse outcomes in older and male patients.(11) Strategies to protect vulnerable, older adults 
should continue to be prioritized and further data adjusted for potential confounders will be 
needed to explore gender related disparities in COVID-19 outcomes. 
We also note racial differences in the epidemiology of COVID-19. African Americans 
represented 64% of all hospitalized COVID-19 patients in our sample. To place this in 
perspective, in the five months preceding March 2020, the proportion of patients admitted to 
our facility who were African American was 21%. Our work does not allow us to explain the root 
causes of these differences however urgent attention is needed to understand and mitigate this 
trend. 
Diabetes mellitus was the most frequently reported co-morbid condition in patients 
hospitalized with COVID-19 in China.(2,4) However,  both our sample and a large series from 
New York City found hypertension to be the most frequent co-morbidity noted in patients 
hospitalized with COVID-19.(11) (2)Interestingly, patients admitted for COVID-19 in our sample 
did not appear to be high utilizers of health care with few prior hospitalizations within our 
system. 
There is data emerging linking obesity and increased disease severity in COVID-19.(12)  
We found similar higher mean BMIs in patients who received MV compared to those who did 
not. However, in those who received MV but died, mean BMIs fell in the overweight category 
with more than a third of those who died having normal BMIs. The interaction between weight, 
need for MV and outcomes when ventilated requires further exploration. 
In terms of presenting symptoms, half the patients in our sample had GI complaints,  higher 
than reports from China where GI symptoms were recorded for only 13% of patients.(13) 
Fewer patients who received MV and died reported fever as a presenting complaint and 
presented with a shorter duration of symptoms. These findings may offer clues to the 
differences in presentation that may signal different trajectories. 
Presenting vital signs between patients in the three outcome groups appeared comparable and 
the high prevalence of meeting SIRS criteria on admission limits its utility as a predictor of 
clinical trajectory. However, q SOFA scoring on admission may prove to be a useful 
prognosticator on admission. Imaging and laboratory evaluations may also be helpful in guiding 
initial clinical concern as the presence of bilateral infiltrates, higher white counts, higher 
absolute neutrophil and BUN values  on admission were noted more frequently in those who 
received MV and died.  
Patients appear to ‘declare’ themselves in the first 48 hours of admission with the mean time to 
reaching maximum oxygen requirements ranging from 32-36 hours following admission. 
Statistically non-significant differences were noted in the times to receiving MV. While the time 
from admission to MV in those who subsequently survived appears to be shorter than the time 
from admission to MV in those who died , we cannot determine whether this observation 
represents a difference in the rate of decline (with slower rates of decline portending worse 
prognosis), an impact on outcomes by early vs late MV or whether the decision to intubate was 
impacted by the team’s awareness of prognosis. 
 
Several laboratory values are being investigated as prognostic markers for severe disease. We 
analyzed the predictive ability of laboratory evaluations in two critical clinical periods posing 
two different decisions. We used the first measured values to  predict the need for mechanical 
ventilation and the peak values to predict inpatient mortality in those who were mechanically 
ventilated. Multiple studies and our own data have demonstrated the marked derangements 
seen in patients with COVID-19.(14) Accordingly, we used cutoff values derived from the 
distribution of  our own data set rather than reference ranges as thresholds to calculate odds 
ratios to present more meaningful and discriminatory interpretations for clinicians. D-dimer 
values have been reported to be abnormal in more than a third of patients presenting in China 
and with values > 1000 ng/mL associated with mortality.(13) Our findings indicate that initial d-
dimer values may also be used to predict the need for mechanical ventilation with values > 
575.5 ng/mL conferring a 10.5 fold increase in risk. Increasing procalcitonin and LDH values 
have also been associated with increased odds of mortality in COVID-19.(4,15) Our findings 
indicate that their first reported values may also predict the need for mechanical ventilation. 
We additionally identified the potential of first and peak BNP values to predict the need for 
mechanical ventilation and mortality respectively. Previous reports have found ferritin and 
troponin values to be predictive of mortality.(5,16) In our sample however these values were 
not statistically significantly different between groups at either first or peak measurement. Our 
findings may form the basis of future work to create scoring systems to improve our ability to 
predict the trajectory of patients presenting with COVID-19, stratify risk and guide subsequent 
management. The differences in the timing of peak values noted for certain laboratory values 
(CK, CRP, ferritin, procalcitonin and troponin)  raise additional areas for future research. 
 
The medical management of these patients appears to be complex and resource intensive with 
multiple complications, long lengths of stay and need for placement upon discharge. In addition 
to shock, venous thromboembolism and secondary bacterial infections, we also noted patients 
with prolonged encephalopathy and sequelae of prolonged intubation. Long-term monitoring is 
needed to identify delayed or prolonged deficits arising from the initial illness. 
 
Our study has limitations. It is a single center’s experience with a novel illness over the first 
month of its appearance at our institution. We relied on discharge summary documentation of 
complications with targeted review of corroborating diagnostics and may therefore be under 
reporting adverse outcomes. While our health system shares an electronic medical record 
platform across all 18 hospitals, we did not access city wide data to confirm readmissions or 
prior hospitalizations. Importantly, we present unadjusted odds ratios and analysis of 
differences between the three outcome groups. The differences found should be considered 
exploratory and hypothesis generating requiring confirmation in larger, multivariate analysis. 
 
As the burden of this novel disease grows, sharing clinical information about patients will help 
us generate hypotheses and adapt our management and prevention strategies. Continued 
research on presentations, outcomes and complications in different settings and over longer 
periods will help improve the care we provide our patients. 
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Table 1: Demographics and Medical Co Morbidities: Adult Admissions for COVID-19 between 
March 1-March 31, 2020 at an Academic Health Center 
 
 
 
Total Did not 
receive 
Mechanical 
Ventilation 
- survived 
Received 
Mechanical 
Ventilation 
- survived 
Received 
Mechanical 
Ventilation 
- died 
p-
value 
 
Total number 140 83 (59.3%) 35 (25.0%) 18 (12.9%)  
Gender     .01 
Female 68 (48.6%) 48 (57.8%) 
1 pregnant 
10 (28.6%) 7 (38.9%)  
Male 72 (51.4%) 35 (42.2%) 25 (71.4%) 11 (61.1%)  
Mean Age (years) 60 57.8 55.8 72.7 .0001 
IQR 48-72 45-69 42-65 67-81  
Race and Ethnicity      
Black 90 (64.3%) 60 (72.3%) 17 (48.6%) 12 (66.7%) .07  
White 37 (26.4%) 16 (19.3%) 13 (37.1%) 5 (27.8%)  
Asian 5 (3.6%) 2 (2.4%) 2 (5.7%) 1 (5.6%)  
Hispanic 7 (5.0%) 5 (6.0%) 2 (5.7%) 0 (0.0%)  
Not recorded 1 (0.7%) 0 (0.0%) 1 (2.9%) 0 (0.0%)  
Healthcare worker 11 (7.9%) 10 (12.0%) 1 (2.9%) 0 (0.0%) .1 
Presented from Group living 5 (3.6%) 5 (6.0%) 0 (0.0%) 0 (0.0%) .3 
Mean number of comorbid 
conditions per patient 
2.9 2.7 2.9 3.2 .4 
IQR 2-4 2-4 2-4 2-4  
Hypertension 96 (68.6%) 53 (63.9%) 25 (71.4%) 14 (77.8%) .4 
Diabetes mellitus 51 (36.4%) 24 (28.9%) 17 (48.6%) 7 (38.9%) .1 
Mean Hemoglobin A1c in the 
last 6 months 
8.3 
n=47 
 
8.5 
n=22 
8.7 
n=16 
7 
n=5 
.5 
Chronic lung disease* 28 (20.0%) 15 (18.1%) 5 (14.3%) 6 (33.3%) .2 
Ischemic heart disease 27 (19.3%) 15 (18.1%) 6 (17.1%) 5 (27.8%) .5 
Congestive heart failure 22 (15.7%) 9 (10.8%) 6 (17.1%) 4 (22.2%) .3 
Mean ejection fraction if echo 
in last 24 months 
48.4 
n=20 
46.2 
n=8 
50.5 
n=6 
38.2 
n=4 
.1 
Immune-suppressed** 12 (8.6%) 6 (7.2%) 3 (8.6%) 3 (16.7%) .5 
Adult asthma 15 (10.7%) 10 (12.0%) 4 (11.4%) 1 (5.6%) .8 
Dialysis dependent 11 (7.9%) 8 (9.6%) 1 (2.9%) 1 (5.6%) .5 
History of malignancy*** 11 (7.9%) 7 (8.4%) 1 (2.9%) 2 (11.1%) .3 
Recent cancer treatment 4 (2.9%) 2 (2.4%) 1 (2.9%) 1 (5.6%) .7 
Transplant recipient**** 4 (2.9%) 3 (3.6%) 1 (2.9%) 0 (0.0%) 1.0 
Stroke/TIA 8 (5.7%) 4 (4.8%) 1 (2.9%) 2 (11.1%) .3 
HIV positive 3 (2.1%) 1 (1.2%) 1 (2.9%) 1 (5.6%) .3 
CD4 counts  418 169 198  
Chronic hepatitis 2 (1.4%) 2 (2.4%) 0 (0.0%) 0 (0.0%) 1.0 
Smoking status      
Current smoker 10 (7.1%) 5 (6.0%) 4 (11.4%) 1 (5.6%) .6 
Never smoker 82 (58.6%) 48 (57.8%) 24 (68.6%) 7 (38.9%) .1 
Mean number of medications 7.6 7 7.7 9 .4 
IQR 3-12 2-10 5-11 6-12  
Angiotensin-converting enzyme 
inhibitor use 
26 (18.6%) 14 (16.9%) 5 (14.3%) 5 (27.8%) .4 
Angiotensin receptor blocker use 29 (20.7%) 17 (20.5%) 9 (25.7%) 3 (16.7%) .7 
Mean BMI 32.4 32.3 36 27.2 .01 
IQR 25-38 25-39 30-38 22-30
BMI Categories 
Underweight (BMI <18.5) 7 (5.0%) 5 (6.3%) 0 (0.0%) 2 (11.1%) .1 
Normal (BMI 18.5-24.9) 25 (17.9%) 15 (19.0%) 1 (2.9%) 7 (38.9%) .002 
Overweight (BMI 25-29.9) 29 (20.7%) 14 (17.7%) 10 (28.6%) 4 (22.2%) .3 
Class I Obesity (BMI 30-34.9) 28 (20.0%) 15 (19.0%) 9 (25.7%) 3 (16.7%) .6 
Class 2 Obesity (BMI 35-39.9) 23 (16.4%) 14 (17.7%) 8 (22.9%) 1 (5.6%) .3 
Class 3 Obesity (BMI 40) 24 (17.1%) 16 (20.3%) 7 (20.0%) 1 (5.6%) .4 
Mean number of hospitalizations 
in the last 12 months 
0.4 0.4 0.3 0.8 .1 
IQR 0-0 0-0 0-0 0-1
Abbreviations: IQR= interquartile range, SD= standard deviation, TIA= transient ischemic attack, 
HIV= human immunodeficiency virus, BMI=body mass index 
 p values comparing the three outcome groups. Total column includes 4 patients whose goals
of care focused on comfort.
*Chronic lung disease =COPD, sarcoidosis, interstitial lung disease, pulmonary hypertension,
cystic fibrosis, restrictive lung disease
**Immune suppressed=chronic steroid use, biologic agents for rheumatologic disorders or
inflammatory bowel disease, recent chemotherapy, hematologic malignancy, history of bone
marrow or solid organ transplant
***Site of malignancy= lung (1), breast (2), colon (1), head and neck (1), renal (1), melanoma
(1), prostate (4), hematologic (1) one patient had both prostate and colon cancer
****2 lung transplant, 2 kidney transplant recipients
Table 2: Details of Initial Clinical Presentation for Adult Admissions for COVID-19 between 
March 1-March 31, 2020 at an Academic Health Center 
 
 Total 
 
 
 
 
Did not 
receive 
Mechanical 
Ventilation - 
survived 
Received 
Mechanical 
Ventilation-
survived 
Received  
Mechanical 
Ventilation 
– died 
p-value 
 
Total number 140 83 35 18  
Mean number of 
symptoms 
4.1 4.5 3.9 2.9 .001 
IQR 3-5 3-6 3-5 2-4  
Symptom Categories     
Respiratory 131 (93.6%) 79 (95.2%) 31 (88.6%) 17 (94.4%) .3 
Gastrointestinal 72 (51.4%) 49 (59.0%) 15 (42.9%) 6 (33.3%) .07 
Fever 91 (65.0%) 59 (71.1%) 23 (65.7%) 7 (38.9%) .03 
Syncope, altered 
mental status 
18 (12.9%) 14 (16.9%) 2 (5.7%) 2 (11.1%) .2 
Constitutional 70 (50.0%) 45 (54.2%) 18 (51.4%) 5 (27.8%) .1 
Mean duration of 
symptoms (days) 
7.7 7.2 9.5 5.4 .009 
IQR 4-10 4-9 5-14 4-7  
Mean first Temperature 
(C) 
37.6 37.6 37.6 37.4 .6 
IQR 37-38 37-38 37-38 36-39  
Mean first systolic BP 
(mmHg) 
133.8 133.3 138 126.7 .2 
IQR 118-148 118-147 120-156 114-142  
Mean first heart rate 
(beats/min) 
98.6 99 99.4 99.9 .9 
IQR 86-110 86-112 85-108 86-111  
Mean first respiratory 
rate (breaths/min) 
22.2 21.5 22.9 23.9 .1 
IQR 18-25 18-24 18-26 19-28  
Met SIRS criteria* 73 (52.1%) 40 (48.2%) 21 (60.0%) 12 (66.7%) .2 
Mean QSOFA score 0.7 0.5 0.9 1.1 .003 
IQR 0-1 0-1 0-1 0-2  
Chest X ray findings     
Normal 19 (13.6%) 15 (18.5%) 2 (5.7%) 1 (5.9%) .1 
Bilateral infiltrates 97 (69.3%) 51 (63.0%) 29 (82.9%) 15 (88.2%) .03 
Unilateral infiltrates 21 (15.0%) 15 (18.5%) 4 (11.4%) 1 (5.9%) .3 
Mean white count 
(k/mm3) 
7.4 6.7 8.2 9.7 .001 
IQR 5-9 5-8 5-10 6-12  
Mean hemoglobin 
(gm/dL) 
13.2 13.2 13.6 12.8 .37 
IQR 12-14 12-14 12-14 10-15  
Mean platelet count 
(k/mm3) 
216.1 228.2 204.7 195.4 .2 
IQR 146-266 151-277 148-254 140-239  
Mean absolute 
neutrophil count 
(k/mm3) 
5.4 4.8 6.3 7.2 .002 
IQR 3-7 3-6 3-7 5-9  
Mean absolute 
lymphocyte count 
(k/mm3) 
1.1 1.1 0.9 1.4 .3 
IQR 0.6-1.2 0.7-1.4 0.6-1.0 0.6-1.0  
Mean sodium (mmol/L) 136.5 136.6 135.8 137.4 .3 
IQR 134-139 134-138 134-138 134-140  
Mean blood urea 
nitrogen (mg/dL) 
24.2 20.3 24.1 37.7 .0009 
IQR 12-29 11-23 13-29 22-51  
Mean creatinine (mg/dL) 1.8 1.8 1.6 2 .8 
IQR 1-2 1-1 1-1 1-2  
Mean glucose (mg/dL) 142.1 132.4 163.1 145.6 .1 
IQR 103-146 102-129 108-166 113-158  
Co-infection by 
Respiratory viral panel 
3/97 
 
3% 
Rhinovirus 
(1) 
Bordatella 
parapertussi
s (1) 
0 Human 
metapneum
ovirus (1) 
 
Abbreviations: IQR=interquartile range, BP= blood pressure 
 p values comparing the three outcome groups. Total column includes 4 patients whose goals 
of care focused on comfort. 
*SIRS= systemic inflammatory response syndrome (met  2 of the following criteria: Temp > 
38C, HR> 90, RR> 20, white count > 12k or < 4k) 
** q SOFA =quick sequential organ failure assessment (1 point each for Glasgow coma scale < 
15, respiratory rate >= 22, systolic BP < = 100) 
 
 
 
 
Table 3: Initial and Peak Laboratory Values in All Patients 
 
Laboratory   All 
Patients 
 
 
Did not 
receive 
mechanical 
ventilation 
- survived 
 Received  
Mechanical 
Ventilation 
- survived 
Received 
Mechanical 
Ventilation 
– died 
p-value 
 
First measured ALT       
Mean value (units/L) 32.9 32.1 35.7 33.9 0.8 
IQR 16-37 14-34 21-41 18-47   
Mean time to first measured 
value (hours) 
8.8 6.9 7.8 19.8 0.05 
Peak measured ALT       
Mean value (units/L) 140 45.2 135.9 445.1 0.00001 
IQR 25-111 16-60 66-160 57-748   
Mean time to peak value 
(hours) 
152.7 101.7 182.9 152.4 0.1 
First measured BNP       
Mean value (pg/mL) 259.6 167.1 144.1 587.4 0.04 
IQR 35-120 39-105 26-101 80-342   
Mean time to first measured 
value (hours) 
1158.5 2450.2 58.2 46 0.5 
Peak measured BNP      
Mean value (pg/mL) 434.8 154 116.4 1276.3 0.001 
IQR 66-423 42-221 56-168 514-1636   
Mean time to peak value 
(hours) 
103.9 78 124.3 103.8 0.3 
First measured CK      
Mean value (units/L) 742.1 463.6 859.9 1820 0.1 
IQR 76-325 78-230 47-273 248-2279   
Mean time to first measured 
value (hours) 
42.1 32 66.5 46.7 0.3 
Peak measured CK      
Mean value (units/L) 1174.1 594.6 1634.9 3130.7 0.03 
IQR 106-1126 100-340 126-1762 1474-2905   
Mean time to peak value 
(hours) 
149.1 84.7 257 153.3 <0.00001 
First measured CRP      
Mean value (mg/dL) 13.3 11 18.7 12.3 0.1 
IQR 5-15 3-12 10-27 8-14   
Mean time to first measured 
value (hours) 
730.3 1239 32.1 15.2 0.7 
Peak measured CRP      
Mean value (mg/dL) 19.9 12.3 27.6 28.7 <0.00001 
IQR 10-28 7-16 23-33 18-41   
Mean time to peak value 
(hours) 
116.2 70.1 147.6 162.9 0.01 
First measured D-dimer      
Mean value (ng/mL) 1874.9 550.1 846.9 6743.2 0.001 
IQR 291-984 234-576 379-886 886-4478   
Mean time to first measured 
value (hours) 
1112.3 33.7 47.4 5534.6 0.1 
Peak measured D-dimer      
Mean value (ng/mL) 5857.5 1605.6 4598.7 13354.7 0.008 
IQR 683-4206 383-1039 930-4056 2528-12396   
Mean time to peak value 
(hours) 
5.6 2.4 14 1.4 0.2 
First measured ferritin      
Mean value (ng/mL) 1211.4 1356.9 1165.2 723.8 0.6 
IQR 275-1044 191-969 379-1324 240-838   
Mean time to first measured 
value 
855.8 1555.1 44.6 46.4 0.6 
Peak measured ferritin      
Mean value (ng/mL) 2740.1 2519.1 1677.7 5477.7 0.1 
IQR 348-2157 289-1325 788-2187 271-3074   
Mean time to peak value 
(hours) 
16.2 0 21.8 7.3 <0.00001 
First measured IL-6      
Mean value (pg/mL) 33.5 12 42.5 35.8 0.08 
IQR 5-38 2-12 8-54 10-30   
Mean time to first measured 
value (hours) 
1398.2 4640.5 59 60.4 0.3 
Peak measured IL-6      
Mean value (pg/mL) 130.4 0 119.9 144.8 <0.00001 
IQR 41-170 0-0 34-170 46-100   
Mean time to peak value 
(hours) 
953.7 1803.4 110.3 164.6 0.6 
First measured LDH      
Mean value (units/L) 432.2 360.9 489.4 562.9 0.0002 
IQR 305-519 260-446 358-579 342-736   
Mean time to first measured 
value (hours) 
24.4 20.7 28.6 30.9 0.5 
Peak measured LDH      
Mean value (units/L) 772.9 448 631.7 1716.2 0.001 
IQR 368-719 316-519 504-696 524-1224   
Mean time to peak value 
(hours) 
63.1 44.6 99.2 86.4 0.2 
First measured procalcitonin      
Mean value (ng/mL) 1.4 0.3 1.8 4.7 0.007 
IQR 0-1 0-0 0-1 0-3   
Mean time to  first measured 
value (hours) 
733.9 11.8 2622.8 14.6 0.2 
Peak measured procalcitonin      
Mean value (ng/mL) 3.2 1.8 2.7 5.6 0.2 
IQR 0-2 0-1 0-2 1-4   
Mean time to peak value 
(hours) 
166.1 0 160.8 173.5 <0.00001 
First measured troponin      
Mean value (ng/mL) 0.3 0 0.8 0.2 0.3 
IQR 0-0 0-0 0-0 0-0   
Mean time to first measured 
value (hours) 
0.6 0 1.8 0.8 0.1 
Peak measured troponin      
Mean value 0.6 0 1.8 0.8 0.1 
IQR 0-0 0-0 0-0 0-1   
Mean time to peak value 
(hours) 
111.6 37.9 133.4 146.2 0.04 
 
 p values comparing the three outcome groups. Total column includes 4 patients whose goals 
of care focused on comfort. 
 
Abbreviations: IQR= interquartile range, ALT=alanine transaminase, BNP= B type natriuretic 
peptide, CK=creatine kinase, CRP= C-reactive protein, LDH= lactate dehydrogenase 
Reference ranges: ALT=7-52, BNP=0-100,CK=30-223,CRP= <1,D-dimer <=292,ferritin=15-400, 
LDH-140-271,procalcitonin= < .5 low risk for sepsis,> 2 high risk for sepsis, troponin <=0.03 
  
Table 4: Unadjusted Odds Ratios for Receiving Mechanical Ventilation and Mortality if 
Mechanically Ventilated Based on Laboratory Evaluation 
Laboratory 
type 
Laboratory 
value 
Cut-off 
threshold 
Outcome Odds 
Ratio
p- value 
First 
measured 
value 
D-Dimer (ng/mL) 575.5 Receive mechanical ventilation 10.5 <0.00001 
Procalcitonin 
(( (ng/mL) 0.24 Receive mechanical ventilation 5.06 0.00004 
LDH (units/L) 445.5 Receive mechanical ventilation 4.46 0.0003 
BNP (pg/mL) 104.75 Receive mechanical ventilation 2.95 0.03 
Peak value 
BNP (pg/mL) 167.5 
Inpatient mortality if 
mechanically ventilated 6.79 0.02 
D-Dimer(ng/mL) 4055.5 
Inpatient mortality if 
mechanically ventilated 2.15 0.3 
LDH (units/L) 695.75 
Inpatient mortality if 
mechanically ventilated 2.15 0.3 
CRP (mg/dL) 33.47 
Inpatient mortality if 
mechanically ventilated 1.69 0.5 
ALT (units/L) 159.75 
Inpatient mortality if 
mechanically ventilated 1.3 0.7 
CK (units/L) 1762 
Inpatient mortality if 
mechanically ventilated 3.05 0.2 
IL-6 (pg/mL) 170 
Inpatient mortality if 
mechanically ventilated 2.06 0.6 
Abbreviations: ALT=alanine transaminase, BNP= brain natriuretic peptide, CK= creatine kinase, 
CRP= c-reactive protein, LDH= lactate dehydrogenase, IL-6= interleukin 6 
Table 5 : Outcomes and Complications for Adult Patients Admitted with COVID-19 Between 
March 1- March 31, 2020 at an Academic Health Center 
Total Did not 
receive 
Mechanical 
Ventilation- 
survived 
Received 
Mechanical 
Ventilation 
- survived
Received 
Mechanical 
Ventilation- 
died 
p- value

Total 140 83 35 18 
Mean length of stay (days) 10.7 6.5 21.3 12.8 .00001 
IQR 4-15 3-8 12-25 8-16
Mean days on ventilator 10.9 NA 11.1 10.6 .03 
IQR 6-14 6-14 6-13
Readmitted within 14 days 11 (7.9%) 7 (8.4%) 4 (11.4%) NA .7 
Shock requiring 
vasopressors 
33 
(23.6%) 
0 (0.0%) 19 (54.3%) 14 (77.8%) 1.0 
Secondary infection 27 
(19.3%) 
3 (3.6%) 15 (42.9%) 8 (44.4%) 2.0 
Adult respiratory distress 
syndrome 
19 
(13.6%) 
0 (0.0%) 13 (37.1%) 6 (33.3%) 2.0 
Acute kidney injury 41 
(29.3%) 
14 (16.9%) 12 (34.3%) 12 (66.7%) .00006 
Venous thromboembolism 15 
(10.7%) 
3 (3.6%) 7 (20.0%) 5 (27.8%) .0007 
New need for renal 
replacement therapy 
10 (7.9%) 0 (0.0%) 4 (11.4%) 6 (33.3%) .000004 
Arrythmias 21 
(15.0%) 
8 (9.6%) 8 (22.9%) 5 (27.8%) .04 
Other complications 37 
(26.4%) 
13 (15.7%) 14 (40.0%) 9 (50.0%) .001 
New O2 requirement upon 
discharge 
3 (2.1%) 2 (2.4%) 1 (2.9%) NA .9 
Discharge disposition not 
home 
16 
(11.4%) 
6 (7.2%) 10 (28.6%) NA .005 
 p values comparing the three outcome groups. Total column includes 4 patients whose goals
of care focused on comfort.
Notes: *** ‘Other’ complications included diabetic ketoacidosis (2), prolonged encephalopathy/ 
delirium (6) thrombocytopenia (2) stridor following extubation (3). 
 IQR= interquartile range, NA= not applicable, O2= oxygen 
